Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of QBX258, a compound developed by
Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with
stage I-II breast cancer related lymphedema.